{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T21:17:25Z","timestamp":1760044645916},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,19]],"date-time":"2014-11-19T00:00:00Z","timestamp":1416355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["dldjournalonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.dld.2014.09.028","type":"journal-article","created":{"date-parts":[[2014,11,11]],"date-time":"2014-11-11T17:43:12Z","timestamp":1415727792000},"page":"S174-S178","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"S5","title":["The evolution of the therapeutic strategy in hepatitis C: Features of sofosbuvir and indications"],"prefix":"10.1016","volume":"46","author":[{"given":"Alfredo","family":"Alberti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Piovesan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2014.09.028_bib0005","series-title":"The burden of liver disease in Europe","author":"European Association for the Study of the Liver","year":"2013"},{"key":"10.1016\/j.dld.2014.09.028_bib0010","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/infdis\/jis385","article-title":"Chronic hepatitis C virus infection increases mortality for hepatic and extrahepatic diseases: a community-based long-term prospective study","volume":"206","author":"Lee","year":"2012","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.dld.2014.09.028_bib0015","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.24641","article-title":"An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guidelines by the American Association for the Study of Liver Diseases","volume":"54","author":"Ghany","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl. 2","key":"10.1016\/j.dld.2014.09.028_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2893.2012.01590.x","article-title":"A practical guide for the use of Boceprevir and Telaprevir for the treatment of hepatitis C","volume":"19","author":"Jacobson","year":"2012","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1016\/j.dld.2014.09.028_bib0025","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1473-3099(13)70074-4","article-title":"Sofosbuvir: the final nail in the coffin for hepatitis C","volume":"13","author":"Manns","year":"2013","journal-title":"Lancet Infectious Diseases"},{"key":"10.1016\/j.dld.2014.09.028_bib0030","series-title":"Sovaldi (sofosbuvir): EU summary of product characteristics","author":"European Medicine Agency","year":"2014"},{"key":"10.1016\/j.dld.2014.09.028_bib0035","series-title":"Sovaldi (sofosbuvir) tablets, for oral use: US prescribing information","author":"Gilead Sciences Inc.","year":"2013"},{"key":"10.1016\/j.dld.2014.09.028_bib0040","first-page":"1067A","article-title":"No clinically significant pharmacokinetic drug\u2013drug interactions between sofosbuvir and HIV antiretrovirals Atripla, rilpivirine, darunavir\/ritonavir, or raltegravir in healthy volunteers","volume":"56","author":"Kirby","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.09.028_bib0045","first-page":"1063A","article-title":"No clinically significant pharmacokinetic drug\u2013drug interactions between sofosbuvir and the immunosuppressants, cyclosporine A or tacrolimus in healthy volunteers","volume":"56","author":"Mathias","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.09.028_bib0050","first-page":"544A","article-title":"Lack of effect of the nucleotide analog polymerase inhibitor PSI-7977 on methadone pharmacokinetics and pharmacodynamics","volume":"54","author":"Denning","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.09.028_bib0055","first-page":"711A","article-title":"In vitro analyses of HCV NS5B S282T mutants in multiple HCV genotypes show low levels of reduced susceptibility to sofosbuvir, no cross resistance to other classes of direct-acting antivirals, and hypersensitivity to ribavirin","volume":"56","author":"Han","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.09.028_bib0060","first-page":"551A","article-title":"Comprehensive resistance testing in patients who relapsed after treatment with sofosbuvir-containing regimens in phase 2 studies","volume":"56","author":"Svarovskaia","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.09.028_bib0065","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1016\/j.dld.2014.09.026","article-title":"Overall efficacy and safety results of sofosbuvir-based therapies in Phase II and III studies","volume":"46","author":"Mangia","year":"2014","journal-title":"Digestive and Liver Disease"},{"key":"10.1016\/j.dld.2014.09.028_bib0070","series-title":"Recommendations for testing, managing and treating hepatitis C","author":"American Association for the Study of Liver Diseases and Infectious Diseases Society of America","year":"2014"},{"key":"10.1016\/j.dld.2014.09.028_bib0075","series-title":"EASL recommendations on treatment of hepatitis C","year":"2014"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865814007348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865814007348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T17:20:40Z","timestamp":1538068840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865814007348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":15,"alternative-id":["S1590865814007348"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2014.09.028","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The evolution of the therapeutic strategy in hepatitis C: Features of sofosbuvir and indications","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2014.09.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}